Health products pricing : clarification of the “industrial criterion”
In a context of increasing supply tensions and stock-outs, the Social Security Financing Act ("LFSS") for…
PLFSS: medical devices soon to be substitutable by pharmacists
Article 31 bis of the Social Security Financing Bill (PLFSS) for 2023 provides for the possibility…
PLFSS: Creation of a specific financing method for advanced therapy medicinal products
The Social Security Financing Bill (PLFSS) for 2023, adopted today in first reading by the Senate,…
PLFSS: New rebates for manufacturers who apply for reimbursement in a limited number of indications
The examination of the Social Security Financing Bill (PLFSS) for 2023 by the deputies began today.…
Biosimilars: the Council of State clarifies the notion of prescription efficiency
Let us recall that an experimental incentive mechanism was introduced on the basis of Article 51…
Real life studies: call for census from the HAS
The collection of real-life data[1] is a central issue for the evaluation of medicinal products and medical…
Reimbursement of innovative medicinal products : the new criterion of relative therapeutic value
Introduced in the Senate on November 25, 2021, the bill on health innovation aims to improve…
man reject gift
“Anti-gift” scheme: figures for the year 2021
The French National Medical Council has published its annual report for the year 2021, in which…
Can a medicinal product be required to be treated identically to other specialties?
The principle of equality requires the administration to settle identical situations in an identical manner[1]. In a…